Unique ID issued by UMIN | UMIN000039134 |
---|---|
Receipt number | R000044632 |
Scientific Title | The efficacy influenced on the timing of anti-VEGF treatment in pro re nata regimen for recurrence of diabetic macular edema |
Date of disclosure of the study information | 2020/01/13 |
Last modified on | 2022/07/15 15:13:07 |
The efficacy influenced on the timing of anti-VEGF treatment in pro re nata regimen for recurrence of diabetic macular edema
The efficacy influenced on the timing of anti-VEGF treatment for DME
The efficacy influenced on the timing of anti-VEGF treatment in pro re nata regimen for recurrence of diabetic macular edema
The timing of anti-VEGF treatment for DME
Japan |
Diabetic macular edema
Ophthalmology |
Others
NO
To investigate whether the efficacy of anti-vascular endothelial growth factor (VEGF) treatment in pro re nata (PRN) regimen for diabetic macular edema (DME) was influenced on the duration until the intravitreal injection of ranibizumab (IVR) and aflibercept (IVA) from the date detected the recurrence of diabetic macular edema (DME).
Efficacy
central retinal thickness, visual acuity
Interventional
Parallel
Non-randomized
Open -but assessor(s) are blinded
Dose comparison
2
Treatment
Medicine |
waiting time is less than 1 week
waiting time is more than 1 month
20 | years-old | <= |
80 | years-old | >= |
Male and Female
Patients with type 2 diabetes with DME who underwent intravitreal injection of anti-VEGF agent in 1+PRN regimen
(1) <20 years of age; 2) focal/grid photocoagulation or panretinal photocoagulation within the previous 6 months; (3) active intraocular inflammation or infection in either eye; (4) uncontrolled glaucoma in either eye; (5) a history of intravitreal injections of steroids during the observational periods; (6) a history of stroke; (7) a systolic blood pressure (BP) > 160 mm Hg, a diastolic BP > 100 mm Hg or untreated hypertension and (8) glycosylated hemoglobin (HbA1c) more than 10%.
50
1st name | Yoshihiro |
Middle name | |
Last name | Takamura |
Faculty of Medical Sciences, University of Fukui
Department of Ophthalmology
918-8205
23-3 Matsuoka, Eiheiji, Yoshida, Fukui, Japan.
+81-776-61-8403
ytakamura@hotmail.com
1st name | Yoshihiro |
Middle name | |
Last name | Takamura |
Faculty of Medical Sciences, University of Fukui
Department of Ophthalmology
918-8205
23-3 Matsuoka, Eiheiji, Yoshida, Fukui, Japan.
+81-776-61-8403
ytakamura@hotmail.com
Faculty of Medical Sciences, University of Fukui
Faculty of Medical Sciences, University of Fukui
Self funding
Faculty of Medical Sciences, University of Fukui
23-3 Matsuoka, Eiheiji, Yoshida, Fukui, Japan.
+81-776-61-8403
ytakamura@hotmail.com
NO
2020 | Year | 01 | Month | 13 | Day |
https://pubmed.ncbi.nlm.nih.gov/34945035/
Published
https://pubmed.ncbi.nlm.nih.gov/34945035/
141
CRT in the deferred group was significantly higher than that in the prompt group at 2, 5, 6, 7, and 12 months (p < 0.05). BCVA in the prompt group was significantly better than that in the deferred group at 7, 10, and 12 months (p < 0.05).
2022 | Year | 07 | Month | 15 | Day |
patients with Diabetic macular edema CRT more than 300 who underwent intraocular injections of ranibizumab or aflibercept in 1 +PRN regimen.
Retrospective, multicenter
None
Central retinal thickness
Visual acuity
number of injections
Main results already published
2019 | Year | 12 | Month | 25 | Day |
2019 | Year | 12 | Month | 19 | Day |
2020 | Year | 01 | Month | 11 | Day |
2020 | Year | 12 | Month | 31 | Day |
2020 | Year | 01 | Month | 12 | Day |
2022 | Year | 07 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044632
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |